Revolution Medicines Stock Quote RVMD - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

37.45

Bid

37.10

Ask

38.20

Volume

1,234,702

36.92 Day's Range 39.25

15.4401 52 Week Range 40.21

Market Cap

37.879M

Previous Close

38.31

Open

39.25

Last Trade

37.8

Last Trade Time

Financial Volume

$ 46,752,885

VWAP

37.8657

Average Volume (3m)

1,487,542

Shares Outstanding

164,690,408

Dividend Yield

PE Ratio

-0.09

Earnings Per Share (EPS)

-2.65

Revenue

11.58M

Net Profit

-436.37M

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include R... Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.revmed.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Revolution Medicines Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker RVMD. The last closing price for Revolution Medicines was $38.31. Over the last year, Revolution Medicines shares have traded in a share price range of $ 15.4401 to $ 40.21.

Revolution Medicines currently has 164,690,408 shares outstanding. The market capitalization of Revolution Medicines is $37.88 million. Revolution Medicines has a price to earnings ratio (PE ratio) of -0.09.

Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024

REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in...

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

Form 4 - Statement of changes in beneficial ownership of securities

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.58	-4.04816807584	39.03	40.21	36.92	1047525	39.09636813	CS
4	0.76	2.0714091033	36.69	40.21	34.23	1244590	37.01512344	CS
12	7.45	24.8333333333	30	40.21	28.43	1487542	33.16926316	CS
26	16.05	75	21.4	40.21	18.79	1440879	29.43624751	CS
52	13.28	54.9441456351	24.17	40.21	15.4401	1579186	27.76278459	CS
156	8.03	27.2943575799	29.42	40.21	14.08	1056575	25.83963431	CS
260	8.1	27.597955707	29.35	56.18	14.08	876602	27.41558419	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CPOPPop Culture Group Company Ltd	$ 3.11 (82.94%)	76.99M
SEZLSezzle Inc	$ 78.82 (76.17%)	779.63k
EMBCEmbecta Corporation	$ 14.18 (38.07%)	2.59M
MCRBSeres Therapeutics Inc	$ 1.02 (36.11%)	16.78M
CCSIConcensus Cloud Solutions Inc	$ 18.00 (36.05%)	1.1M
EMKREMCORE Corporation	$ 1.09 (-62.41%)	5.66M
TIVCTivic Health Systems Inc	$ 0.59 (-55.97%)	8.84M
CTMXCytomX Therapeutics Inc	$ 2.04 (-51.31%)	41.56M
RAPTRAPT Therapeutics Inc	$ 4.65 (-41.73%)	4.88M
NPCENeuropace Inc	$ 7.96 (-36.83%)	452.6k
GWAVGreenwave Technology Solutions Inc	$ 0.07 (20.48%)	189.65M
SGDSafe and Green Development Corporation	$ 0.84 (35.48%)	101.01M
SQQQProShares UltraPro Short QQQ	$ 10.68 (-0.56%)	97.21M
FFIEFaraday Future Intelligent Electric Inc	$ 0.0406 (-2.87%)	79.34M
NKLANikola Corporation	$ 0.5765 (-0.45%)	77.17M